Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Next Previous
X
Search
Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Alternative Names: Men Quad TT; MenACYW conjugate vaccine; Meninge ACTW conj - Sanofi; Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine; MenQuadfi; Quadrivalent Meningococcal Conjugate Vaccine; TetraMen-T

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group A infections
  • Registered Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Meningococcal-group-A-infections(In adolescents, In children, In infants, Prevention, In adults) in Unknown (IM, Injection)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Meningococcal-group-C-infections(In adolescents, In children, In infants, Prevention, In adults) in Unknown (IM, Injection)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Meningococcal-group-W-135-infections(In adolescents, In children, In infants, Prevention, In adults) in Unknown (IM, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top